» Articles » PMID: 8707085

Supplementary Enteral Nutrition Maintains Remission in Paediatric Crohn's Disease

Overview
Journal Gut
Specialty Gastroenterology
Date 1996 Apr 1
PMID 8707085
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Liquid diets given enterally combined with "bowel rest' are efficacious in the treatment of active Crohn's disease, but rapid recrudescence of gastrointestinal symptoms after resumption of a normal diet is common.

Aims: This study examined whether continuation of enteral nutrition as a nocturnal supplement to an ad libitum daytime intake of a normal diet increased the length of remission of Crohn's disease in children.

Patients And Methods: Children and adolescents with active Crohn's disease treated successfully with exclusive enteral nutrition were classified retrospectively according to whether they continued supplementary enteral nutrition or not. Time to relapse and linear growth were compared between the two cohorts.

Results: Between January 1986 and December 1992, 65 patients aged 7-17 years (mean (SD) 13.6 (2.1) years) (36 males, 29 females) with Crohn's disease in exacerbation were treated for > or = four weeks by bowel rest and nasogastric tube feeding of an oligopeptide or amino acid based formula. At first follow up visit, remission (fall in Paediatric Crohn's Disease Activity Index, PCDAI to < or = 20) was achieved in 47 of 65 (72%) patients. Subsequently, 20 of these 47 (43%) relapsed by six months and 28 of 47 (60%) by 12 months. Patients who continued nasogastric supplementary feeding (n = 28) after resumption of an otherwise normal diet remained well longer than those who discontinued nocturnal supplements completely (n = 19) (p < 0.02). Furthermore, continued use of nasogastric supplements before completion of puberty was associated with improved linear growth.

Conclusion: After successful treatment of active Crohn's disease by exclusive enteral nutrition, supplementary enteral nutrition without restriction of normal diet is associated with prolongation of remission and improved linear growth in children and adolescents.

Citing Articles

Tryptophan metabolites profile predict remission with dietary therapy in pediatric Crohn's disease.

Sigall Boneh R, van der Kruk N, Wine E, Verburgt C, de Meij T, Lowenberg M Therap Adv Gastroenterol. 2025; 18:17562848251323004.

PMID: 40012837 PMC: 11863242. DOI: 10.1177/17562848251323004.


Role of diet in prevention versus treatment of Crohn's disease and ulcerative colitis.

Halmos E, Godny L, Vanderstappen J, Sarbagili-Shabat C, Svolos V Frontline Gastroenterol. 2024; 15(3):247-257.

PMID: 38665795 PMC: 11042448. DOI: 10.1136/flgastro-2023-102417.


The microbiome landscape in pediatric Crohn's disease and therapeutic implications.

Fetter K, Weigel M, Ott B, Fritzenwanker M, Stricker S, de Laffolie J Gut Microbes. 2023; 15(2):2247019.

PMID: 37614093 PMC: 10453987. DOI: 10.1080/19490976.2023.2247019.


Global attitudes on and the status of enteral nutrition therapy for pediatric inflammatory bowel disease.

Luo J, Xie Y, Wu M, Zhao J, Hu L Front Med (Lausanne). 2022; 9:1036793.

PMID: 36569124 PMC: 9773139. DOI: 10.3389/fmed.2022.1036793.


Dietary Therapy to Improve Nutrition and Gut Health in Paediatric Crohn's Disease; A Feasibility Study.

Allen S, Belnour S, Renji E, Carter B, Bray L, Allen A Nutrients. 2022; 14(21).

PMID: 36364868 PMC: 9655551. DOI: 10.3390/nu14214598.


References
1.
Lochs H, Steinhardt H, Zeitz M, Vogelsang H, Sommer H, Fleig W . Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology. 1991; 101(4):881-8. DOI: 10.1016/0016-5085(91)90711-s. View

2.
Hyams J, Ferry G, Mandel F, GRYBOSKI J, Kibort P, Kirschner B . Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12(4):439-47. View

3.
Lindor K, Fleming C, Burnes J, Nelson J, Ilstrup D . A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. Mayo Clin Proc. 1992; 67(4):328-33. DOI: 10.1016/s0025-6196(12)61547-x. View

4.
Polk D, Hattner J, Kerner Jr J . Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn's disease. JPEN J Parenter Enteral Nutr. 1992; 16(6):499-504. DOI: 10.1177/0148607192016006499. View

5.
SINGLETON J, Hanauer S, Gitnick G, Peppercorn M, Robinson M, WRUBLE L . Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993; 104(5):1293-301. DOI: 10.1016/0016-5085(93)90337-c. View